Evidence map›Paper›PMID 28056864›Full record

ArticleBMC nephrology2017

Skin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysate.

Bernd Ramsauer, Gerwin Erik Engels, Reindert Graaff, Aleksandar Sikole, Stefan Arsov, Bernd Stegmayr

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Role of skin autofluorescence in managing renal and cardiac diseases in outpatient dermatology.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Bernd RamsauerDepartment of Public Health and Clinical Medicine, Umea University, Umea, Sweden. bernd.ramsauer@vgregion.se.ORCID http://orcid.org/0000-0002-5872-0583
Gerwin Erik EngelsHaemoScan BV, Groningen, The Netherlands.
Reindert GraaffUMC Staff and Department of Endocrinology, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands.
Aleksandar SikoleUniversity Ss Cyril and Methodius, Hospital of Nephrology, Skopje, Republic of Macedonia.
Stefan ArsovUniversity Ss Cyril and Methodius, Institute for Epidemiology and Biostatistics, Skopje, Republic of Macedonia.
Bernd StegmayrDepartment of Public Health and Clinical Medicine, Umea University, Umea, Sweden.
Ss. Cyril and Methodius University in Skopje · MKSkaraborg Hospital · SEUmeå University · SEUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHaemodialysis (HD) patients suffer from an increased risk of cardiovascular disease (CVD). Skin autofluorescence (SAF) is a strong marker for CVD. SAF indirectly measures tissue advanced glycation end products (AGE) being cumulative metabolites of oxidative stress and cytokine-driven inflammatory reactions. The dialysates often contain glucose.

methodsAutofluorescence of skin and plasma (PAF) were measured in patients on HD during standard treatment (ST) with a glucose-containing dialysate (n = 24). After that the patients were switched to a glucose-free dialysate (GFD) for a 2-week period. New measurements were performed on PAF and SAF after 1 week (M1) and 2 weeks (M2) using GFD. Nonparametric paired statistical analyses were performed between each two periods.

resultsSAF after HD increased non-significantly by 1.2% while when a GFD was used during HD at M1, a decrease of SAF by 5.2% (p = 0.002) was found. One week later (M2) the reduction of 1.6% after the HD was not significant (p = 0.33). PAF was significantly reduced during all HD sessions. Free and protein-bound PAF decreased similarly whether glucose containing or GFD was used. The HD resulted in a reduction of the total PAF of approximately 15%, the free compound of 20% and the protein bound of 10%. The protein bound part of PAF corresponded to approximately 56% of the total reduction. The protein bound concentrations after each HD showed the lowest value after 2 weeks using glucose-free dialysate (p < 0.05). The change in SAF could not be related to a change in PAF.

conclusionsWhen changing to a GFD, SAF was reduced by HD indicating that such measure may hamper the accumulation and progression of deposits of AGEs to protein in tissue, and thereby also the development of CVD. Glucose-free dialysate needs further attention. Protein binding seems firm but not irreversible.

trial registrationISRCTN registry: ISRCTN13837553 . Registered 16/11/2016 (retrospectively registered).

Indexed as

AdultAgedAged, 80 and overBiomarkersCardiovascular DiseasesFemaleGlucoseGlycation End Products, AdvancedHemodialysis SolutionsHumansMaleMiddle AgedOptical ImagingRenal DialysisReproducibility of ResultsRetrospective StudiesBiomarkersGlucoseGlycation End Products, AdvancedHemodialysis SolutionsGlucose free dialysateHaemodialysisPlasma autofluorescenceSkin autofluorescence

Identifiers

PMID28056864
PMCPMC5217331
OpenAlexW2570869377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.